pym50028
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2004 (NCT00130429)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- epi-sarsasapogenin
- epismilagenin
- pym50028
- pym50028
- pym50028
- pym50028
- pym 50028
- pym-50028
- sarsaponin
- sarsasapogenin
- sarsasapogenin, (3beta,5alpha,25r)-isomer
- sarsasapogenin, (3beta,5alpha,25s)-isomer
- sarsasapogenin, (3beta,5beta,25r)-isomer
- sarsasapogenin, (3beta,5beta,25s)-isomer
- sarsasapogenin, (3beta,5beta)-isomer
- smilagenin
- tigogenin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01060878 | Phase 2 | Nov 1, 2010 | Phytopharm |
| NCT00130429 | Phase 2 | Jan 1, 2004 | Phytopharm, University of Oxford |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Phytopharm | For profit | 2 | 2 | 1 | 2004 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2004 |
2 organizations
Page 1 / 1